NanoCytomics Awarded $1.5 million NIH Grant for Further Investigation of its Lung Cancer Screening Test

Share Article

Funding enables optimization of technology prior to commercialization by Preora Diagnostics

John W. Hart President & CEO Preora Diagnostics

"This is an important milestone along our path to making dramatic improvements in cancer survival rates.”

Preora Diagnostics Inc., a privately held medical technology company developing low-cost and highly accurate cancer screening tests, today announced that NanoCytomics LLC, the product development company that licenses its technology to Preora for potential commercialization of cancer screening tests, has been awarded a $1,497,000 “Direct to Phase II” grant from the National Institutes of Health (NIH) for its lung cancer screening test.

The NIH grant is for two years and does not require a follow-up application in order to receive the full amount of financial support. “This award will enable NanoCytomics to develop and optimize a regulatory-compliant, self-contained Partial Wave Spectroscopy (PWS) Nanocytology system,” said Preora Diagnostics President and CEO John W. Hart. “Although additional funding will be required for clinical studies and other prerequisite activities before we can bring our lung cancer screening test to the marketplace, it is an important milestone along our path to making dramatic improvements in cancer survival rates.”

Hariharan Subramanian, PhD, co-founder and chief technology officer, NanoCytomics, added, “We appreciate the support that NIH continues to provide us through this grant. It allows us to validate the systems, protocols and nanocytology biomarkers that would maximize sensitivity to early-stage lung cancers. We intend to conduct these studies with 500 subjects, at least 160 of whom will have been previously diagnosed with early-stage lung cancer.”

About Preora Diagnostics
Preora Diagnostics Inc. is dedicated to helping people survive cancer through a proven, two-tiered approach to early detection. The company develops proprietary, low-cost, minimally invasive, highly sensitive and highly specific cancer screening tests using technology that detects and measures cellular changes at the nanoscale level. The screening tests are based on the proprietary Partial Wave Spectroscopy (PWS) Nanocytology platform, licensed exclusively by Preora through NanoCytomics, LLC and Northwestern University. For more information, visit http://www.PreoraDx.com.

About NanoCytomics, LLC
Recognizing their shared values and their ability to collaborate effectively, Vadim Backman, PhD; Hariharan Subramanian, PhD; and Hemant Roy, MD formed NanoCytomics LLC in 2011 based on the PWS Nanocytology technology platform that emerged from Dr. Backman’s Biophotonics Laboratory at Northwestern University’s McCormick School of Engineering. Their resulting research efforts spawned a new field, nanocytology, which today is the foundation for the company’s new product development efforts to revolutionize early cancer detection.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jed Weiner
White Oak Communications, Inc.
+1 (847) 910-1330
Email >
@jedweiner
since: 04/2009
Follow >
Visit website